Table 5. Utility.
| Elbasha et al.40 | Elbasha and Dasbach45 | Jit et al.46 | Kim and Goldie47 | Kim43 | Taira et al.42 | Zechmeister et al.41 | Olsen and Jepsen48 | Chesson et al.49 | |
|---|---|---|---|---|---|---|---|---|---|
| Method | Multiplic. | Additive (?) | Multiplic. | n/a | n/a | Not used – life-years gained only | Multiplic. (?) | QALY loss per case | |
| Baseline utility | Based on data from the US National Health Interview Survey and the Healthy People 2000 study | n/a | US Beaver Dam Study | n/a | US Beaver Dam Study | Unpublished Danish data (method not reported) | Not reported | ||
| CIN | CIN 1: 0.91 CIN 2/3: 0.87 CIS: 0.87 |
CIN 1: 0.012* CIN 2: 0.065* CIN 3: 0.054* |
n/a | n/a | SIL: 0.97** | CIN 1: 0.9333 CIN 2/3: 0.8658 |
CIN 1/2: 0.03/0.07 for 18 mos CIN 3: 0.2 for 4 mos and 0.03 for 2 y |
||
| Cervical cancer | Loc.: 0.76 Reg.: 0.67 Dist.: 0.48 |
S I: 0.35* S II: 0.44* S III: 0.44* S IV: 0.52* |
Loc.: 0.76 (over 5 y) Reg.: 0.67 (over 5 y) Dist.: 0.48 (lifetime) |
- | S I: 0.79** S II-IV: 0.62** |
S I: 0.7598 S II-IV: 0.6693 |
Loc., reg. and dist. = 0.36, 0.41 and 0.45 for 3 y, followed by death | ||
|
Cervical cancer survivor |
0.76 | S I: 0.10* S II: 0.15* S III: 0.15* S IV: 0.38* |
- | S I: 0.90** S II-IV: 0.62** Well: 1.00** |
n/a | Loc.: 0.27 for 4 mos and then a further 0.07 Reg. and dist.: 0.37/0.45 for 3 y and then a further 0.1/0.24 |
|||
| Other cancers | - | Same as cervical cancer | - | 0.68 (lifetime) | 0.68 (Anal) | - | - | The same as cervical | |
| Genital warts | 0.91 (8.5 mo in average in Elbasha 2010) | 0.039* | 0.91 (3 mo) | 0.91 | - | 0.9142 | Sex-specific, combination of 3 decrements (0.05–0.15) and 2 duration (3 mos and 6 mos) | ||
| RRP | - | 0.80 | - | 0.69 (JO, over 4 y) | - | - | - | 1.05 QALYs per case | |
Multiplic, multiplicative; HALex, Health and Activities Limitation Index; QWB, Quality of Well-Being; TTO, time trade-off; CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ; SIL, squamous intraepithelial lesion; Loc., localized; Reg., regional; Dist., distant; S, stage; mo, months; RRP, recurrent respiratory papillomatosis; JO, juvenile-onset. *Utility decrement. ** Not clear if it is a decrement or a utility weight.